



AccuPlex™ Quality Solutions for Respiratory Disease Diagnostics

ASSAY VERIFICATION AND ONGOING PERFORMANCE MONITORING FOR ROUTINE PATIENT TESTING

HIGHLIGHTS

NON-INFECTIOUS AND REPLICATION DEFICIENT; ENSURES SAFE HANDLING IN CONTRAST TO VIRAL SAMPLES

FULLY EXTRACTABLE WITH A REAL VIRAL PROTEIN COAT; SUPERIOR TO "NAKED" TRANSCRIBED RNA

OPTIMIZED FOR ASSAY VERIFICATION AND DAY-TO-DAY PERFORMANCE MONITORING

2 YEAR STABILITY AT 2 – 8°C

Whether your laboratory is utilizing multiplex or sequential molecular testing workflows, AccuPlex™ offers quality solutions with targets for SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV). These full-process quality solutions are designed to challenge the entire molecular test procedure from extraction to detection, ensuring clinical laboratories can have confidence in their assay results. Products are released using the US CDC Influenza SARS-CoV-2 (Flu-SC2) Multiplex Assay and Cepheid GeneXpert® Xpress SARS-CoV-2 and Flu/RSV Assays.

AccuPlex Verification Panels are optimized for assay verification at installation by documenting test performance along the assay’s range, enabling laboratories to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency.

AccuPlex Reference Material and Molecular Controls Kits are designed to measure day-to-day performance of the assay, providing both a positive and negative reference solution.

MULTIPLEXED SOLUTIONS

SARS-CoV-2, Flu A/B and RSV

Product Description	Material Numbers	Pack Size	Concentration
AccuPlex SARS-CoV-2, Flu A/B and RSV Verification Panel	0505-0183	Positive 1 1 x 3 mL Positive 2 1 x 3 mL Positive 3 1 x 3 mL Negative 1 x 3 mL	100,000 copies/mL 10,000 copies/mL 1,000 copies/mL 5,000 copies/mL (RNase P)
AccuPlex SARS-CoV-2, Flu A/B and RSV Reference Material Kit	0505-0174	Positive 5 x 1.5 mL Negative 5 x 1.5 mL	5,000 copies/mL 5,000 copies/mL (RNase P)

Not for In Vitro Diagnostic Use. Research Use Only.

SEQUENTIAL SOLUTIONS

SARS-CoV-2

Product Description	Material Numbers	Pack Size	Concentration
AccuPlex SARS-CoV-2 Verification Panel*	0505-0168	Positive 1 1 x 3 mL Positive 2 1 x 3 mL Positive 3 1 x 3 mL Negative 1 x 3 mL	100,000 copies/mL 10,000 copies/mL 1,000 copies/mL 5,000 copies/mL (RNase P)
AccuPlex SARS-CoV-2 Molecular Controls Kit**	0505-0159	Positive 5 x 1.5 mL Negative 5 x 1.5 mL	5,000 copies/mL 5,000 copies/mL (RNase P)

**Not for In Vitro Diagnostic Use. Research Use Only.*

***For In Vitro Diagnostic Use. CE-IVD marked.*

Flu A/B and RSV

Product Description	Material Numbers	Pack Size	Concentration
AccuPlex Flu A/B and RSV Verification Panel	0515-0002	Positive 1 1 x 3 mL Positive 2 1 x 3 mL Positive 3 1 x 3 mL Negative 1 x 3 mL	100,000 copies/mL 10,000 copies/mL 1,000 copies/mL 5,000 copies/mL (RNase P)
AccuPlex Flu A/B and RSV Reference Material Kit	0515-0001	Positive 5 x 1.5 mL Negative 5 x 1.5 mL	5,000 copies/mL 5,000 copies/mL (RNase P)

Not for In Vitro Diagnostic Use. Research Use Only.

To learn more about AccuPlex SARS-CoV-2 Quality solutions visit:

www.seracare.com/SARSCoV2 or contact customer service at 800.676.1881

ABOUT SERACARE

TRUSTED SUPPLIER
TO DIAGNOSTIC
MANUFACTURERS AND
CLINICAL LABS FOR
OVER 30 YEARS

HIGH-QUALITY
CONTROL PRODUCTS,
RAW BIOLOGICAL
MATERIALS, AND
IMMUNOASSAY
REAGENTS

INNOVATIVE TOOLS
AND TECHNOLOGIES
TO PROVIDE
ASSURANCE IN
DIAGNOSTIC ASSAY
PERFORMANCE AND
TEST RESULTS

FOR MORE
INFORMATION, PLEASE
VISIT OUR WEBSITE:
WWW.SERACARE.COM

Table 1: Regions included in AccuPlex Positive Reference Material

Virus	Genbank Accession #	Strain Information	Regions Included
Influenza A	KU933490 - KU933497	A/Michigan/45/2015(H1N1)	Full Genome
Influenza B	CY236601.1 - CY236608.1	B/Colorado/06/2017	Full Genome
RSV	NC_001803	Subtype A	1..4380; 8460..15191
SARS-CoV-2	NC_045512.2	Wuhan-Hu-1	Full Genome

LGC SeraCare's AccuPlex recombinant material serves as a true full process molecular control for your diagnostic assays. Compatible with multiplexed RT-PCR and NGS-based assays, AccuPlex custom recombinant materials are constructed with a replication-deficient mammalian virus, producing a safe, non-infectious material (Figure 1). With a protein coat and lipid bilayer, these mammalian virus-based reference materials resemble the complexity of virus targets found in true patient samples.




FIGURE 1: 1) RNA sequence from the pathogenic virus of interest is chosen. 2) DNA synthesis and cloning occur to produce the recombinant RNA. 3) Recombinant RNA and helper RNA are co-transfected into the mammalian cells, allowing the encapsulation of recombined RNA. 4) Exocytosis of the mature enveloped non-infectious and replication deficient RNA virus containing the assay target RNA sequence of interest

MOST 'PATIENT SAMPLE-LIKE' MATERIAL EVALUATES ENTIRE WORKFLOW

Unlike RNA-spiked buffer, or technologies that package viral RNA into a bacteriophage, the AccuPlex recombinant closely resembles the wild-type mammalian pathogenic virus. This enables the release of the viral genome at a similar rate to the wild-type virus during the nucleic acid sample preparation process. AccuPlex recombinant material mimics a real patient sample in your workflow, serving as a full-process control for your assay.

ACCUPLEX SOLVES ASSAY DEVELOPMENT CHALLENGES

If you're developing diagnostics for emerging viral diseases and have the challenge of including safe, non-infectious controls in your test kit, partner with SeraCare's talented R&D team to produce your custom AccuPlex recombinant virus material (DNA or RNA-based). Utilizing your sequences of interest and product specifications, we will develop a custom solution which meets your unique requirements.

ORDERING INFORMATION

To place an order, or learn more about our SARS-CoV-2 Quality Solutions, please contact us at +1.508.244.6400 and 800.676.1881 or email customerservice@seracare.com.